🧪 About the Drug
- Generic Name: Rifaximin Tablets, 550 mg
- Reference Brand: Xifaxan®
- Use: Treatment of IBS-D in adults
- US Market Size: $2,672.9 million (as per IQVIA MAT March 2025)
EduDecode: IBS-D is that thing where your stomach disagrees with every buffet you ever loved. And Rifaximin is the peace treaty.
🏭 Where It’ll Be Made
- Zydus’ manufacturing site atSEZ
- II, Ahmedabad
- This plant is already part of Zydus’ US exports ecosystem
📦 Zydus’ USFDA Track Record
| Metric | Count |
|---|---|
| ANDA Filings (since FY04) | 492 |
| ANDA Approvals | 427 |
| Current Filing Status | Tentative Approval |
Tentative= Approved from a quality/safety standpoint, but launch delayed due to patent exclusivity or litigation.
🧠 EduInvesting Take
Zydus is showing up to the
To Read Full 16 Point ArticleBecome a member